Senti Biosciences Holdings (SNTI) Debt Ratio (2021 - 2024)

Senti Biosciences Holdings (SNTI) posted quarterly Debt Ratio of 0.0 for Q3 2024, up 50.57% quarter-over-quarter from 0.0 in Q2 2024.

Senti Biosciences Holdings (SNTI) Debt Ratio (2021 - 2024) Analysis & Trends

Senti Biosciences Holdings' Debt Ratio history runs 2 years deep, the most recent figure standing at 0.0 for Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.05
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.03
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.47
10	Senti Biosciences Holdings	12.06 Mn	12.06 Mn	-	0.12

Download Data